Niemann-Pick Disease Type C - cyclotherapeutics
Por um escritor misterioso
Descrição
Potential treatment for Niemann-Pick type C, a rare neurodegenerative disease
Progression of Niemann–Pick type C disease in mice and humans
TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C - cyclotherapeutics
Miglustat in Niemann-Pick disease type C patients: a review, Orphanet Journal of Rare Diseases
Niemann-Pick Disease Drug Type C Treatment Market Size
Niemann-Pick Type C (NPC) Market Outlook and Forecast - Thelansis
Impaired Autophagy in the Lipid-Storage Disorder Niemann-Pick Type C1 Disease - ScienceDirect
Niemann-Pick Disease Type C Treatment Market Size & Trends 2020- expected to reach US$ 378.8 Million With CAGR of 42.3% by 2027, Orphazyme A/S, Cyclo Therapeutics, Inc., and Johnson & Johnson
Niemann-Pick Disease Clinical Trial (Phase 3) Enrolling Patients
NiemannPick: a debilitating disease with fatal outcomes. Learn more about our Phase 3 program for #NPC1 here: Cyclo Therapeutics, Inc. posted on the topic
de
por adulto (o preço varia de acordo com o tamanho do grupo)
